Protease Inhibitors in Development

Bristol-Myers, Gilead Work on New Combo HIV Pill (October 27, 2011)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Tibotec and Gilead Team Up to Develop Prezista/Cobicistat Combo (July 5, 2011)
From Test Positive Aware Network
Brecanavir Shows Good Cross-Resistance Profile (August 17, 2006)
In XVI International AIDS Conference
Brecanavir Shows Favorable Pharmacokinetics When Combined With Select PIs in Double-Boosted Regimens (August 15, 2006)
In XVI International AIDS Conference
New Drugs From Old Classes (Spring 2006)
A listing of NNRTIs, NRTIs and protease inhibitors currently in development.
To read PDF, click here.
In ACRIA Update, from AIDS Community Research Initiative of America
New Protease Inhibitor Brecanavir Shown to Be Safe and Effective in Small Study (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy
Safety and Pharmacokinetic Data for 640385, a New Protease Inhibitor in Development (February 24, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from TheBodyPRO.com
Drug Development News: Gilead (May/June 2004)
A new prodrug technology targeting lymphocytes could all but revolutionize protease inhibitor therapy.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Gilead Aims to Begin Evaluation of New Protease Inhibitor (January 13, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
Out of the Lab: A New Target and a New Agent From Gilead (December 2003)
A study examines the anti-HIV properties of a betulinic acid derivative, and Gilead hopes to begin human studies of a new protease inhibitor.
In GMHC Treatment Issues, from Gay Men's Health Crisis
Satellite Symposia: New and Up-and-Coming PIs (September 2003)
2nd International AIDS Society Conference on HIV Pathogenesis and Treatment.
In IAPAC Monthly, from International Association of Physicians in AIDS Care
Protease Inhibitors (Summer/Autumn 2002)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation

More Most Viewed Articles

HIV Tools You Can Use

Track Your CD4 Count, Viral Load and More: Use TheBody.com's Health Tracker

TheBody.com's App for iPhones
TheBody.com's Medication and Health Reminders
TheBody.com's Facebook, Widgets, RSS Feeds and Twitter
Are You at Risk for HIV? Take Our Quiz!
U.S. ASO Finder U.S. ASO Listings
International ASOs

The Body is a service of Remedy Health Media, LLC, 250 West 57th Street, New York, NY 10107. The Body and its logos are trademarks of Remedy Health Media, LLC, and its subsidiaries, which owns the copyright of The Body's homepage, topic pages, page designs and HTML code. General Disclaimer: The Body is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through The Body should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.